Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Stock Transaction

Sentiment:

SEC Form 4 Filing


Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports disposition of shares to cover tax obligations arising from vesting of restricted stock units.

Summary

  • On April 30, 2024, Gao Hanlin, the Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), disposed of 79 shares of common stock.
  • The shares were disposed of to satisfy tax withholding obligations related to the vesting of restricted stock units granted on April 30, 2021.
  • The transaction price was $20.35 per share.
  • Following the transaction, Gao Hanlin beneficially owns 927,732 shares of Fulgent Genetics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't indicate a change in the executive's overall confidence in the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction is related to tax obligations arising from stock-based compensation, a common practice in publicly traded companies.

Key Dates

DateDescription
04/30/2021Date of grant of restricted stock units that led to the tax obligation.
05/03/2021Date of original Form 4 filing reporting the grant of restricted stock units.
04/30/2024Date of the stock transaction (disposal of shares).
05/02/2024Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.